Evidence map›Paper›PMID 41566486›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2026

Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study.

Stephen D Betschel, Hugo Chapdelaine, Remi Gagnon, M Dawn Goodyear, Paul K Keith, Ahmed El-Zoeiby, Natalie Khutoryansky, Daniel N Castaner

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03845400 (An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03845400 completednot on this map

An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)

TypeobservationalSponsorShireRan2019 to 2022Enrolled168ConditionsHereditary Angioedema (HAE)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stephen D BetschelDepartment of Medicine, Division of Clinical Immunology and Allergy, University of Toronto, Toronto, ON, Canada.
Hugo ChapdelaineCentre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada.
Remi GagnonClinique Spécialisée en Allergie de la Capitale, Quebec, QC, Canada.
M Dawn GoodyearDivision of Hematology and Hematologic Malignancies, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Paul K KeithDepartment of Medicine, Division of Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada.
Ahmed El-ZoeibyTakeda Canada Inc., Bay Adelaide Centre, 22 Adelaide Street West, Suite 3800, Toronto, ON, M5H 4E3, Canada. ahmed.elzoeiby@takeda.com.
Natalie KhutoryanskyTakeda Development Center Americas, Inc., Lexington, MA, USA.
Daniel N CastanerTakeda Development Center Americas, Inc., Lexington, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe EMPOWER Study (NCT03845400) was a phase 4, observational, non-interventional, multicenter study evaluating the real-world effectiveness and safety of lanadelumab in patients with hereditary angioedema (HAE). This subanalysis focused on lanadelumab effectiveness and safety in patients from Canada.

methodsEnrollment included patients with HAE due to C1 inhibitor deficiency. Patients were categorized as "newly treated" or "established on lanadelumab" if they had received fewer than four or at least four doses before enrollment, respectively.

resultsThirteen patients from Canada were enrolled: seven newly treated and six established on lanadelumab; these patients received lanadelumab for a mean (standard deviation [SD]) duration of 315 (224) and 536 (366) days, respectively, during the study. In newly treated patients, the mean (SD) observed HAE attack rate decreased after lanadelumab initiation from 1.5 (2.9) to 0.3 (0.6) attacks per month. In patients established on lanadelumab, the mean (SD) observed HAE attack rate was 0.1 (0.1) attacks per month throughout the study. Most HAE attacks were mild or moderate in severity (newly treated, 94%; established on lanadelumab, 100%). No study discontinuations were attributed to treatment-emergent adverse events. All treatment-emergent adverse events were non-severe, non-serious, and unrelated to lanadelumab treatment.

conclusionsLanadelumab lowered the HAE attack rate among newly treated Canadian patients and maintained a low attack rate among those previously established on lanadelumab, demonstrating robust effectiveness across both patient groups. Effectiveness, tolerability, and safety of lanadelumab were consistent with the overall population from the EMPOWER Study, supporting the use of lanadelumab as a first-line long-term prophylactic treatment for patients with HAE in Canada.

trial registrationNCT03845400, registered February 19, 2019.

Indexed as

CanadaEffectivenessHereditary angioedemaLanadelumabLong-term prophylaxisReal-world dataSafety

Identifiers

PMID41566486
PMCPMC13011278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.